Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Early Polymyalgia Rheumatica
NCT04027101Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in polymyalgia rheumatica (PMR), sponsored by Centre Hospitalier Universitaire de Brest. Started Dec 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT04027101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027101.